We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression.
- Authors
Martín-Penagos, Luis; Fernández-Fresnedo, Gema; Benito-Hernández, Adalberto; Mazón, Jaime; de Cos, Marina; Oviedo, María Victoria; San Segundo, David; López-Hoyos, Marcos; Gómez-Román, Javier; Carlos Ruiz, Juan; Rodrigo, Emilio
- Abstract
Background and objective: About 25% of patients with IgA nephropathy (IgAN) progress to stage 5 chronic kidney disease (CKD) after years of evolution. Various tools have been developed in recent years designed to predict which of the patients will had poorer outcomes. The value of circulating galactosyl-deficient IgA1 (Gd-IgA1) has been related to a worse evolution of IgAN in several studies. There are also some publications that relate higher APRIL values with a worse evolution. Recently, a new method has been developed that allows measuring the value of circulating Gd-IgA1 in a simpler way than those previously available. The objective of this study is to analyze the influence of circulating Gd-IgA1, measured by this method, on the progression of IgAN. Materials and methods: Forty-nine patients with a diagnosis of IgAN demonstrated by renal biopsy were selected in our center, without having received prior immunosuppressive treatment, for whom frozen serum was available. The median follow-up was 4 years. Gd-IgA1 was measured by lectin-independent ELISA with the monoclonal antibody KM55 (IgA1 kit Cat. No. 30111694. IBL Int., Hamburg, Germany). Likewise, APRIL levels were also measured in these patients. Results: 19 (38.8%) patients reached stage 5 CKD. The fourth quartile of circulating Gd-IgA1 was related to a higher cumulative risk of reaching stage 5 CKD in the Kaplan-Meier analysis (risk at the 5th year 39.4% vs. 24.3%, log rank p = 0.019). The Gd-IgA1 value was related to an increased risk of CKD stage 5 (HR 1.147, 95% CI 1.035-1.270, p = 0.009), regardless of glomerular filtration rate, proteinuria, the percentage of sclerosed glomeruli and the value of segmental sclerosis. We did not find significant differences in the APRIL values. Conclusions: The value of circulating Gd-IgA1 measured by the monoclonal antibody KM55 is related to a worse evolution of patients with IgAN independently of other variables, so it could be included in the study of patients to improve the prediction of the risk of disease progression.
- Subjects
HAMBURG (Germany); MONOCLONAL antibodies; GLOMERULAR filtration rate; CHRONIC kidney failure; RENAL biopsy; DIAGNOSIS
- Publication
Nefrologia, 2021, Vol 41, Issue 3, p311
- ISSN
0211-6995
- Publication type
Article
- DOI
10.1016/j.nefroe.2021.06.004